ImmunityBio (NASDAQ:IBRX) Shares Up 2.4% – Still a Buy?

ImmunityBio, Inc. (NASDAQ:IBRX) shares shot up 2.4% on Friday . The stock traded as high as $9.80 and last traded at $9.78. 28,541,428 shares were traded during trading, a decline of 37% from the average session volume of 45,534,469 shares. The stock had previously closed at $9.55.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced completion of enrollment in its pivotal randomized Phase 2 trial of ANKTIVA plus BCG vs BCG alone in BCG‑naïve NMIBC CIS — early completion reduces timeline uncertainty for a potential label‑expanding readout and supports commercial upside for ANKTIVA. Article Title
• Positive Sentiment: Analyst/valuation commentary highlights trial progress and strong ANKTIVA commercial momentum — positive narratives that can support higher forward earnings expectations and investor confidence. Article Title
• Neutral Sentiment: ImmunityBio will host a business update and review FY‑2025 financial results on March 3 — the call could drive volatility depending on revenue, guidance, and clinical updates management provides. Article Title
• Neutral Sentiment: HC Wainwright published a Q1 earnings forecast for ImmunityBio — analyst forecasts and any accompanying model changes will influence near‑term analyst sentiment and target‑price revisions. Article Title
• Negative Sentiment: Director Barry Simon sold 75,000 shares at an average price of $12.01 (disclosed Feb 24) — insider selling can be interpreted by some investors as a signal to reduce exposure, contributing to downward pressure. Article Title
• Negative Sentiment: Reports cite significant intraday profit‑taking (one article notes a ~17% drop after an intraday high) and coverage pointing to a ~7% decline — these articles reflect short‑term selling and headline‑driven volatility that can amplify swings in the stock. Article Title Article Title

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IBRX. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a research report on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research note on Monday. BTIG Research lifted their target price on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group upped their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.60.

ImmunityBio Stock Performance

The business’s 50 day simple moving average is $5.12 and its 200-day simple moving average is $3.32. The company has a market cap of $10.05 billion, a price-to-earnings ratio of -25.74 and a beta of 0.16.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million during the quarter. Research analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Insider Buying and Selling at ImmunityBio

In related news, Director Christobel Selecky sold 50,000 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the transaction, the director owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 501,967 shares of company stock worth $4,466,412. 69.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Slow Capital Inc. bought a new position in shares of ImmunityBio in the 3rd quarter valued at approximately $25,000. Truist Financial Corp acquired a new position in ImmunityBio during the third quarter valued at approximately $27,000. Swiss Life Asset Management Ltd acquired a new stake in shares of ImmunityBio in the third quarter worth $27,000. WealthPlan Investment Management LLC bought a new stake in shares of ImmunityBio during the 4th quarter worth $27,000. Finally, Diversify Advisory Services LLC bought a new stake in shares of ImmunityBio during the 2nd quarter worth $27,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.